Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Carmustine
Drug ID BADD_D00371
Description A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)
Indications and Usage For the treatment of brain tumors, multiple myeloma, Hodgkin's disease and Non-Hodgkin's lymphomas.
Marketing Status Prescription
ATC Code L01AD01
DrugBank ID DB00262
KEGG ID D00254
MeSH ID D002330
PubChem ID 2578
TTD Drug ID D01OXI
NDC Product Code 70121-1482; 50683-0017; 76339-121; 0781-3474; 59651-168; 24338-050; 68475-503; 54893-0055; 23155-649; 57821-002; 55718-139; 23155-790; 43598-628; 59981-034; 70710-1525; 58621-002; 57884-0032; 54879-036; 23155-261; 71288-126
Synonyms Carmustine | BCNU | N,N'-Bis(2-Chloroethyl)-N-Nitrosourea | FIVB | 1,3-Bis(2-Chloroethyl)-1-Nitrosourea | BiCNU | Nitrumon
Chemical Information
Molecular Formula C5H9Cl2N3O2
CAS Registry Number 154-93-8
SMILES C(CCl)NC(=O)N(CCCl)N=O
Chemical Structure
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal pain07.01.05.002--
Abscess11.01.08.001--Not Available
Acute leukaemia01.10.02.001; 16.01.02.001--Not Available
Agitation17.02.05.012; 19.06.02.001--
Alopecia23.02.02.001--
Altered state of consciousness17.02.04.001; 19.07.01.0030.002398%Not Available
Amnesia17.03.02.001; 19.20.01.001--
Anaemia01.03.02.001--
Anaplastic astrocytoma16.30.02.004; 17.20.02.004--Not Available
Anxiety19.06.02.002--
Aphasia17.02.03.001; 19.21.01.0010.004263%
Arrhythmia02.03.02.001--Not Available
Asthenia08.01.01.001--Not Available
Ataxia08.01.02.004; 17.02.02.001--
Azotaemia20.01.01.001--Not Available
Back pain15.03.04.005--
Blood bilirubin increased13.03.01.008--
Body temperature increased13.15.01.001--Not Available
Brain abscess11.01.03.003; 17.06.07.0010.001332%Not Available
Brain herniation12.01.10.001; 17.11.01.0020.000139%Not Available
Burning sensation08.01.09.029; 17.02.06.001--Not Available
Cerebral haemorrhage17.08.01.003; 24.07.04.0010.000208%Not Available
Cerebral infarction17.08.01.004; 24.04.06.0020.004263%Not Available
Cerebrospinal fluid leakage12.01.10.004; 17.02.05.0010.001865%
Chest pain02.02.02.011; 08.01.08.002; 22.02.08.003--Not Available
Coma17.02.09.001--Not Available
Confusional state17.02.03.005; 19.13.01.001--
Conjunctival haemorrhage06.07.01.001; 24.07.05.001--Not Available
Conjunctival oedema06.04.01.001--Not Available
Constipation07.02.02.001--
The 1th Page    1 2 3 4 5    Next   Last    Total 7 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene